Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Omega Diagnostics Group PLC Launches VISITECT® CD4 Point-of-care Test

Published: Wednesday, June 27, 2012
Last Updated: Wednesday, June 27, 2012
Bookmark and Share
Company has announced the imminent launch of VISITECT® CD4, a point-of-care (POC) disposable test for the detection of CD4 T-cell levels, aimed at reaching HIV-positive patients across the globe.

VISITECT® CD4, developed by the Burnet Institute in Melbourne, Australia, is an affordable POC test that enables CD4 T-cell levels to be determined, quickly and conveniently, even in remote rural areas in resource-poor countries. This easy-to-use, semi-quantitative lateral flow test uses a finger-prick blood sample and produces a straightforward visual result in just 40 minutes, enabling patients to receive life-saving antiretroviral treatment before leaving the clinic. Minimal training is required and no additional instruments are necessary, eliminating the need for sophisticated equipment, expensive reagents and highly trained personnel.

Associate Professor David Anderson, Deputy Director of the Burnet Institute and leader of the team that developed the test, added: “According to UNAIDS, there are 15 million people who should be getting access to antiretroviral therapy but aren’t, just because they can’t get access to an affordable CD4 test in their communities. This test will provide access for even the most remote and disadvantaged patients.”
Andrew Shepherd, Founder and Chief Executive of Omega Diagnostics added: “This test overcomes many of the limitations commonly associated with the traditional technique of flow cytometry, offering a cost-effective means of obtaining immediate CD4 results. Establishing when a patient should commence therapy will improve health and help to reduce transmission of the virus, benefitting the entire population.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
New Therapeutic Target for Crohn’s Disease
A promising new target for drugs that treat IBD has been identified along with a possible biomarker for IBD severity.
Researchers Find Fungus-Fighting Compound
A compound has been identifed that blocks growth of a fungus responsible for lung infections and allergic reactions.
Analysing 10,000 Cells Simultaneously
New techniquethat traps 10,000 cells on a single chip has potential for cancer screening for individuals.
Peer Reviewed Study Demonstrates Mass Spec Technique
The peer reviewed study demonstrates MS workflow, TMTCalibrator workflow, which dramatically enhances detection of key early stage Alzheimer’s biomarkers.
Small Molecules Lead to a Big Change in Reaction Outcomes
Scientists have changed the behaviour of a group of molecules involved in carbon-oxygen bond synthesis.
Enhancing Antibiotics to Defeat Resistant Bacteria
Scientists enhance ability of antibiotics to defeat resistant types of bacteria using molecules called PPMOs
Sanger Institute, St Jude Data-Sharing Agreement
Childhood cancer targeted by Sanger Institute and St Jude Children’s Research Hospital exchanges of cancer data
Over Two-Thirds of Cervical Cancer Deaths Prevented
Cervical screening prevents 70% of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83%.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!